NEW YORK (
TheStreet) -- The last time I talked about health care giant
Johnson & Johnson
(JNJ - Get Report) I said the stock
looked "too healthy".
Aside from concerns about the company's valuation, I didn't feel comfortable about Johnson & Johnson's margins; nor did I feel that the company's top-selling drug, Zytiga, was the answer to long-term prosperity.
My biggest source of anxiety stemmed from the competition for which Johnson & Johnson seemed to be unprepared. One threat was from
(MDVN - Get Report).
In that article, I said:
"I do wonder, though, how JNJ will respond to increased competition and further threats of weakening margins.
"Companies like Medivation -- which has a strong oral medication drug that rivals Zytiga -- should not be taken lightly. This is where JNJ's extraordinarily well-diversified business should offset potential near-term headwinds."
Well, it's taken two months but investors have finally gotten some answers. On Monday, Johnson & Johnson announced it agreed to acquire privately held
for $650 million in upfront cash. It may pay as much as $1 billion if certain milestones are met.
The deal gives Johnson & Johnson rights to Aragon's ARN-509, a prostrate cancer drug now in Phase II development. That may weaken Medivation, whose drug Xtandi has become a dominant force in battling prostate cancer.
Medivation has been fighting Aragon to keep ARN-509 off the shelves, suggesting that Medivation holds the rights to the drug -- claims that have led to legal action.
In the middle of all of this has been Aragon, which has had difficulty financing ARN-509's development. But with Johnson & Johnson, financing will not be an issue. Medivation's management, which now sees potentially faster development of a competing drug, understands that.
But they also understand that ARN-509 will complement Zytiga's strengths and give Johnson & Johnson the ability to take on new approaches to treat prostate cancer patients that Johnson & Johnson would have otherwise not considered. That forces the hand of Medivation, which is not in a position to take risks.
I'm not suggesting Johnson & Johnson has effectively killed any of Medivation's growth potential. The deal is just one move in a long chess game. Plus, the purchase still has to pass regulatory approval -- although I believe it will.
In the meantime, Medivation still has legal pieces it can play, even if that only serves to sedate Johnson & Johnson's momentum. But will it matter?
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts